Tagged with AI

Quintiles Thailand Asia is rapidly becoming a new frontier for drug development as Western companies seek to develop and register their products in Asia, while emerging Asian companies seek new capabilities to globalize products. We hear a lot of positive sounds and enthusiasm from MNCs about the environment in Thailand: available pool…

AstraZeneca Thailand Dr. Seeto, this is your first head of country position for AZ! Looking back at your first year-and-a-month, what have been the highlights and the key lessons learnt? Firstly, leading the Thai country organization has been a real privilege and honor. Looking back, I am proud of how the country…

The Government Pharmaceutical Organization (G Dr. Witit, when we interviewed your predecessor in 2006, we talked about the vital role and leading position GPO plays in the Thai pharmaceutical industry and the company’s investments in manufacturing facilities to improve access and affordability of drugs. What have been some of the most important milestones since you…

Zuellig Pharma Thailand ‘When markets are inefficient, relationships are important. When markets are more efficient, relationships become less important because the markets become more systematic, professional, and objective in the way they operate,’ said Mr. Zwisler, former CEO of Zuellig Pharma Asia Pacific when we interviewed him in China. At which development stage…

Novo Nordisk Thailand Novo Nordisk is one of the very few pharmaceutical multinationals that have a strong focus on one therapeutic area. Although the company has a presence in other disease areas, diabetes remains its leading cause. Could you give us a brief overview of the evolution of diabetes in Thailand compared to…

Genzyme (Shanghai) In 2006, Genzyme’s global CEO, Henri Termeer, said he is “personally very interested in China” and that he expects the company to build a capable infrastructure in ten years. We’re now 30% closer to the deadline. How has this deep commitment to China resulted in developments in the country and…

Fountain Medical Development You have an MD and you’ve worked in industry, but then you decided to become and entrepreneur. What challenges did you face in transitioning to starting your own company and in growing your organization? Entrepreneurship is nothing new in China. Half the population of this country seems to want to…

Medicilon/MPI Preclinical Research Shanghai You completed your higher education in the US and worked there for a period afterwards; what caused you to move back to China and start this company? A lot of people are now returning to China after gaining extensive experience in the US. I personally enjoyed the vast experience that…

Roche Thailand Dr Ammelburg, you have been working for Roche for more than 25 years now, time essentially spent between your home country Germany and Thailand. After more than 10 years spent here, what would you consider to be the main specificities of the Thai Pharma industry? The Thai market is not…

Association of International Pharmaceutical Manufactures (AIPM) When Focus Reports prepared a report on the French pharmaceutical industry in 2009/10, we found that the head of the main multinational pharmaceutical association had taken a career path quite similar to yours: he had been an administrator and head of the regulatory authority; he subsequently left the administration and…

Invida Thailand You are General Manager for Thailand and Vietnam; two markets that certainly interest companies but at a very different stage of development. What are according to you the main differences between the Thai and the Vietnam market? Government regulation in Vietnam is higher throughout the value chain, whereas Thailand tends…

Bayer Thailand Mr. Ammelburg of Roche described Thailand as a very difficult and different market and according to PReMA figures there was only 2 percent growth last year. Nevertheless, global projections rank Thailand as 12th among emerging countries in pharma and anticipate Thailand becoming the eighth largest economy and market by 2016.…